Nuts, Just a thought. If PRR has global manufacturing facilities for CVac could it not then licence out the trial and delivery side for other cancers to other Pharmas with Prima Biomed to receive goodwill payments and royalties in those cases. Is this possibly far fetched on my part.
Also I interpret the early move to other cancers with potentially massive markets, am I being too presumptuous in believing they must be really confident that the ovarian cancer trial will be successful? Am I missing something here?
Given Marc Voigt is based in Germany is this where the action with other Pharmas likely to come from? It was Germany that provided Prima with a $5mill grant.
cheers
big phamas and more mentioned at agm, page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.8¢ | 29.0¢ | $539.5K | 1.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 214062 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 469318 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |